<DOC>
	<DOCNO>NCT01345786</DOCNO>
	<brief_summary>For contraceptive application film-coated tablet develop combine nomegestrol acetate ( NOMAC ) estradiol ( E2 ) . This open-label , randomize , single-dose , four-way , replicate , cross-over study design conduct 2 parallel part two site , one site per study part . The primary objective Part 1 ass bioequivalence NOMAC E2 drug product manufacture use commercial process ( `` commercial batch '' ) versus Phase 3 drug product ( `` Batch A '' ) . The primary objective Part 2 ass bioequivalence NOMAC E2 drug product manufacture use commercial process ( `` commercial batch '' ) versus Phase 3 drug product ( `` Batch B '' ) .</brief_summary>
	<brief_title>Bioequivalence Nomegestrol Acetate ( NOMAC ) Estradiol ( E2 ) Commercial Versus Phase 3 Pivotal Clinical Batches NOMAC-E2 Tablets ( P06328 )</brief_title>
	<detailed_description />
	<criteria>Key Healthy postmenopausal female age 45 70 year , inclusive , Body Mass Index ( BMI ) 18 32 , inclusive ; Free clinically significant disease would interfere study evaluation . Key Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug ; History infectious disease affect subject 's ability participate trial ; History alcohol drug abuse past 2 year ; Previously receive NOMACE2 ; Current participation another clinical study participate clinical study ( eg , laboratory clinical evaluation ) within 30 day baseline ; Smoked 10 cigarette equivalent tobacco use per day ; History malignancy ; Contraindications use contraceptive steroid ; Recent history medication use certain medication specify protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>